Tests atogepant tablets to prevent chronic migraine in teens
Tests atogepant tablets against placebo in people aged 12 to 17 with chronic migraine.
Key facts
- Who runs it
- AbbVie
- Where
- Amherst, Anaheim, Ann Arbor, Austin, Bountiful, Clinton, Evansville, Fayetteville, Fresno, Greensboro, Gulf Breeze, Houston, Huntsville, Kingwood, Lakeland, Little Rock, Long Beach, Miami, Nashua, Nashville, Oceanside, Papillion, Philadelphia, Ridgeland, Salt Lake City, San Jose, Scottdale, Smithfield, Walnut Creek, Waxahachie, Weston, and Winter Park, United StatesSee the 32 sitesAlso in 10 other countries, 34 sites
- Trial code
- Registry title
- A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 420 people, planned
- Started
- 13 Feb 2025
- Expected to end
- Mar 2031
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Atogepant
- Placebo for Atogepant
- Record updated
- 9 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teenagers aged 12 to 17 years who have had chronic migraine for at least 6 months. They would take atogepant or a placebo once a day for 12 weeks.
- Age
- 12 to 17 years
- Sex
- All sexes can join.
- Disease stage
- Chronic migraine, with or without aura, diagnosed for at least 6 months. In the last 28 days of screening, the eDiary must show 15 or more headache days and 8 or more migraine days.
Main reasons for not taking part
- Clinically significant high blood pressure, in the investigator's judgment
- Any clinically significant blood, hormone, lung, kidney, liver, stomach and bowel, heart or nervous system disease in the past
- Not having completed the eDiary on at least 20 of the last 28 days of screening
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- History of chronic migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3) (2018) for at least 6 months as of Visit 1
- During the last 28 days of the screening/baseline period, and as per eDiary:; Participant must have completed the eDiary for a minimum of 20 out of 28 days; Participant has >= 15 headache days; Participant has >= 8 migraine days
Who cannot take part
- Clinically significant hypertension per investigator's judgment
- History of any clinically significant hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, cardiovascular or neurologic disease
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 17 years old?
Where in United States
Also in 10 other countries, 34 sites
- Dent Neurologic Institute - AmherstAmherst, United StatesTaking people
- Advanced Research CenterAnaheim, United StatesTaking people
- Michigan Headache & Neurological InstituteAnn Arbor, United StatesTaking people
- UT Health Austin at Dell Childrens Neurology ClinicAustin, United StatesTaking people
- Pantheon Clinical ResearchBountiful, United StatesTaking people
- Alpine Research Organization - ClintonClinton, United StatesTaking people
- Deaconess Midtown HospitalEvansville, United StatesTaking people
- Preferred Research Partners - FayettevilleFayetteville, United StatesNo longer taking part
- Neuro Pain Research CenterFresno, United StatesTaking people
- Headache Wellness CenterGreensboro, United StatesNo longer taking part
- Northwest Florida Clinical Research Group, LLCGulf Breeze, United StatesTaking people
- Earle ResearchHouston, United StatesTaking people
- Rehabilitation and Neurological ServicesHuntsville, United StatesTaking people
- Frontier Clinical Research - KingwoodKingwood, United StatesTaking people
- Auzmer ResearchLakeland, United StatesNo longer taking part
- Preferred Research PartnersLittle Rock, United StatesTaking people
- Alliance for Research Alliance for WellnessLong Beach, United StatesTaking people
- My Preferred ResearchMiami, United StatesTaking people
- Healthy Perspectives - Innovate Mental Health ServicesNashua, United StatesTaking people
- Access Clinical Trials IncNashville, United StatesTaking people
- Excell ResearchOceanside, United StatesTaking people
- Cct Research - Papillion Research CenterPapillion, United StatesTaking people
- The Children's Hospital of PhiladelphiaPhiladelphia, United StatesTaking people
- Proven Endpoints LLCRidgeland, United StatesTaking people
- Highland Clinical ResearchSalt Lake City, United StatesTaking people
- Lumos Clinical Research CenterSan Jose, United StatesTaking people
- Frontier Clinical Research - ScottdaleScottdale, United StatesTaking people
- Frontier Clinical Research - SmithfieldSmithfield, United StatesTaking people
- Sunwise Clinical ResearchWalnut Creek, United StatesTaking people
- Clinpoint TrialsWaxahachie, United StatesTaking people
- Encore Medical Research - WestonWeston, United StatesTaking people
- Pediatric Neurology & Epilepsy Center Of Central Florida - Winter ParkWinter Park, United StatesTaking people
About the trial
What the trial wants to find out
Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. The goals of the study are to evaluate adverse events and how well treatment of atogepant works compared to placebo (looks like the study treatment but contains no medicine) in preventing chronic migraine in participants between 12 and 17 years of age.
Read full original descriptionShow less
Atogepant is a medicine currently approved in the United States and Europe for the preventive treatment of migraine in adult patients with migraine and is being studied for the preventative treatment of chronic migraine in participants between the ages of 12 and 17 years. Participants will be randomly assigned to one of the 2 groups to be treated with either atogepant or placebo. This study is double-blinded, which means that neither the patients nor the study doctors know who is given which study treatment. Approximately 420 participants 12 to 17 years of age with chronic migraine will be enrolled at approximately 70 sites across the world.
Participants will receive oral tablets of atogepant or placebo once daily for 12 weeks and will be followed for 4 weeks.
Participants will attend regular visits during the study at a hospital or clinic and the effects of treatment will be checked by completion of a daily diary, medical assessments, blood tests, checking for side effects, and completing questionnaires.
The 2 groups in the trial
- AtogepantTreatment being tested
Participants will receive atogepant once daily for 12 weeks.
- Placebo for AtogepantPlacebo, for comparison
Participants will receive placebo for atogepant once daily for 12 weeks.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age
- Plain-language title
- Tests atogepant tablets to prevent chronic migraine in teensGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06810505, who can take part
- Publications
- Record updated
- 9 October 2026